Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties
Background: During myocardial infarction (MI), billions of cardiomyocytes are lost. The optimal therapy should effectively replace damaged cardiomyocytes, possibly with stem cells able to engraft and differentiate into adult functional cardiomyocytes. As such, cardiac atrial appendage stem cells (CA...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/13/2964 |
| _version_ | 1797528028995125248 |
|---|---|
| author | Lize Evens Ellen Heeren Jean-Luc Rummens Annelies Bronckaers Marc Hendrikx Dorien Deluyker Virginie Bito |
| author_facet | Lize Evens Ellen Heeren Jean-Luc Rummens Annelies Bronckaers Marc Hendrikx Dorien Deluyker Virginie Bito |
| author_sort | Lize Evens |
| collection | DOAJ |
| description | Background: During myocardial infarction (MI), billions of cardiomyocytes are lost. The optimal therapy should effectively replace damaged cardiomyocytes, possibly with stem cells able to engraft and differentiate into adult functional cardiomyocytes. As such, cardiac atrial appendage stem cells (CASCs) are suitable candidates. However, the presence of elevated levels of advanced glycation end products (AGEs) in cardiac regions where CASCs are transplanted may affect their regenerative potential. In this study, we examine whether and how AGEs alter CASCs properties in vitro. Methods and Results: CASCs in culture were exposed to ranging AGEs concentrations (50 µg/mL to 400 µg/mL). CASCs survival, proliferation, and migration capacity were significantly decreased after 72 h of AGEs exposure. Apoptosis significantly increased with rising AGEs concentration. The harmful effects of these AGEs were partially blunted by pre-incubation with a receptor for AGEs (RAGE) inhibitor (25 µM FPS-ZM1), indicating the involvement of RAGE in the observed negative effects. Conclusion: AGEs have a time- and concentration-dependent negative effect on CASCs survival, proliferation, migration, and apoptosis in vitro, partially mediated through RAGE activation. Whether anti-AGEs therapies are an effective treatment in the setting of stem cell therapy after MI warrants further examination. |
| first_indexed | 2024-03-10T09:52:19Z |
| format | Article |
| id | doaj.art-e9d0004e79234f79869d00f3c7f52d3f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T09:52:19Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-e9d0004e79234f79869d00f3c7f52d3f2023-11-22T02:42:51ZengMDPI AGJournal of Clinical Medicine2077-03832021-07-011013296410.3390/jcm10132964Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells PropertiesLize Evens0Ellen Heeren1Jean-Luc Rummens2Annelies Bronckaers3Marc Hendrikx4Dorien Deluyker5Virginie Bito6BIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBIOMED, UHasselt—Hasselt University, Agoralaan, 3590 Diepenbeek, BelgiumBackground: During myocardial infarction (MI), billions of cardiomyocytes are lost. The optimal therapy should effectively replace damaged cardiomyocytes, possibly with stem cells able to engraft and differentiate into adult functional cardiomyocytes. As such, cardiac atrial appendage stem cells (CASCs) are suitable candidates. However, the presence of elevated levels of advanced glycation end products (AGEs) in cardiac regions where CASCs are transplanted may affect their regenerative potential. In this study, we examine whether and how AGEs alter CASCs properties in vitro. Methods and Results: CASCs in culture were exposed to ranging AGEs concentrations (50 µg/mL to 400 µg/mL). CASCs survival, proliferation, and migration capacity were significantly decreased after 72 h of AGEs exposure. Apoptosis significantly increased with rising AGEs concentration. The harmful effects of these AGEs were partially blunted by pre-incubation with a receptor for AGEs (RAGE) inhibitor (25 µM FPS-ZM1), indicating the involvement of RAGE in the observed negative effects. Conclusion: AGEs have a time- and concentration-dependent negative effect on CASCs survival, proliferation, migration, and apoptosis in vitro, partially mediated through RAGE activation. Whether anti-AGEs therapies are an effective treatment in the setting of stem cell therapy after MI warrants further examination.https://www.mdpi.com/2077-0383/10/13/2964stem cellsaldehyde dehydrogenaseCASCsglycated proteinsadvanced glycation end productsproliferation |
| spellingShingle | Lize Evens Ellen Heeren Jean-Luc Rummens Annelies Bronckaers Marc Hendrikx Dorien Deluyker Virginie Bito Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties Journal of Clinical Medicine stem cells aldehyde dehydrogenase CASCs glycated proteins advanced glycation end products proliferation |
| title | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties |
| title_full | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties |
| title_fullStr | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties |
| title_full_unstemmed | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties |
| title_short | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties |
| title_sort | advanced glycation end products impair cardiac atrial appendage stem cells properties |
| topic | stem cells aldehyde dehydrogenase CASCs glycated proteins advanced glycation end products proliferation |
| url | https://www.mdpi.com/2077-0383/10/13/2964 |
| work_keys_str_mv | AT lizeevens advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT ellenheeren advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT jeanlucrummens advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT anneliesbronckaers advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT marchendrikx advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT doriendeluyker advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties AT virginiebito advancedglycationendproductsimpaircardiacatrialappendagestemcellsproperties |